Moleculin Biotech has priced a best-efforts public offering expected to raise approximately $9.3 million. The offering consists of 12,376,667 shares of common stock, or pre-funded warrants in lieu thereof, together with warrants to purchase up to 37,130,001 additional shares, at a combined price of $0.75 per share and associated warrant. The common warrants are immediately exercisable at $0.75 per share and expire five years from the initial exercise date. The company intends to use the net proceeds to advance its lead drug candidate Annamycin through clinical development and for working capital. Roth Capital Partners is acting as exclusive placement agent, with Maxim Group LLC serving as financial advisor, and the offering is expected to close on or about August 3, 2026, subject to customary conditions.
Moleculin Biotech IncPricing a public offering dilutes existing shareholders.